NCT00041756

Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 395 (actual)
• Sponsor: Procter and Gamble · Industry
• Sex: All
• Age: 40 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Matrix metalloproteinases (MMPs) have been implicated in the cartilage degradation. PG-530742 inhibits some MMPs, potentially limiting cartilage degradation and disease progression. This study will test the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.

Detailed description

Matrix metalloproteinases have been implicated in the cartilage degradation that occurs in osteoarthritis. PG-530742 inhibits some of these matrix metalloproteinases, thus potentially limiting cartilage degradation and disease progression. This study will test the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.

Conditions

• Osteoarthritis, Knee

Interventions

Type	Name	Description
DRUG	PG-530742	One 25 mg PG-530742 tablet, twice daily for for one year
DRUG	Placebo	One placebo tablet, twice daily for for one year
DRUG	50 mg PG-530742	One 50 mg PG-530742 tablet, twice daily for for one year
DRUG	100 mg PG-530742	100 mg PG-530742 tablet, twice a day for one year
DRUG	200 mg PG-530742	200 mg PG-530742 tablet, twice a day for one year

Timeline

• Start date: 2002-07-01
• Primary completion: 2004-02-01
• Completion: 2004-02-01
• First posted: 2002-07-17
• Last updated: 2011-11-08
• Results posted: 2011-11-08

Locations

23 sites across 2 countries: Hungary, United Kingdom